RT Journal Article
T1 One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study
A1 Cobo Dols, Manuel
A1 Beato Zambrano, Carmen
A1 Cabezon-Gutierrez, Luis
A1 Chicas-Sett, Rodolfo
A1 Blancas Lopez-Barajas, Maria Isabel
A1 Garcia Navalon, Francisco Javier
A1 Firvida Perez, Jose Luis
A1 Serrano Bermudez, Gala
A1 Togores Torres, Pilar
A1 Delgado Mingorance, Ignacio
A1 Giraldo Marin, Alexandra
A1 Libran Oriol, Anna
A1 Paredes Lario, Alfredo
A1 Sanchez Maurino, Pedro
A1 Higuera Gomez, Oliver
A1 Moreno Munoz, Diana
A1 Huerta Gonzalez, Ibone
A1 Sanz-Yague, Almudena
A1 Soler Lopez, Begona
K1 constipation
K1 cancer
K1 pain
K1 Induced bowel dysfunction
K1 Pooled analysis
K1 Noncancer pain
K1 Prevalence
K1 Pathophysiology
K1 Validation
K1 Management
K1 Disorders
K1 Severity
AB Objectives Naloxegol is a peripherally acting mu-opioid receptor antagonist (PAMORA) for treatment of opioid-induced constipation (OIC). The main objective was to analyse the long-term efficacy, quality of life (QOL) and safety of naloxegol in patients with cancer in a real-world study. Methods This one-year prospective study included patients older than 18 years, with active oncological disease who were under treatment with opioids for pain control and Karnofsky >= 50 and OIC with inadequate response to treatment with laxative (s). All the patients received treatment with naloxegol according to clinical criteria. The main efficacy objectives were measured by the patient assessment of constipation QOL questionnaire (PAC-QOL), the PAC symptoms (PAC-SYM), the response rate at day 15, and months 1-3-6-12, and global QOL (EuroQoL-5D-5L). Results A total of 126 patients (58.7% males) with a mean age of 61.5 years (95% CI 59.4 to 63.7) were included. PAC-SYM and PAC-QOL total score and all their dimensions improved from baseline (p= 50 and OIC with inadequate response to treatment with laxative (s). All the patients received treatment with naloxegol according to clinical criteria. The main efficacy objectives were measured by the patient assessment of constipation QOL questionnaire (PAC-QOL), the PAC symptoms (PAC-SYM), the response rate at day 15, and months 1-3-6-12, and global QOL (EuroQoL-5D-5L). Results A total of 126 patients (58.7% males) with a mean age of 61.5 years (95% CI 59.4 to 63.7) were included. PAC-SYM and PAC-QOL total score and all their dimensions improved from baseline (p
PB Bmj publishing group
SN 2045-435X
YR 2021
FD 2021-03-11
LK https://hdl.handle.net/10668/25895
UL https://hdl.handle.net/10668/25895
LA en
DS RISalud
RD Apr 11, 2025